E-LIB Suche - Ergebnisse für: Rediti, M.

1

10P PIK3CA mutation and response to neoadjuvant taselisib a..:

Fimereli, D. ; Nuciforo, P.G. ; de Azambuja, E....
ESMO Open. 9 (2024) - p. 103019 , 2024

Link: https://doi.org/10.1016/..

2

Integrating spatial and single cell transcriptomics to iden..:

Serra, M. ; Papagiannis, A. ; Rediti, M....
European Journal of Cancer. 200 (2024) - p. 113620 , 2024

Link: https://doi.org/10.1016/..

3

Unravelling tumor heterogeneity in patients with HER2-low h..:

Fimereli, D. ; Serra, M. ; Rediti, M....
European Journal of Cancer. 200 (2024) - p. 113834 , 2024

Link: https://doi.org/10.1016/..

4

15P Portraying HER2-positive breast cancer heterogeneity wi..:

Rediti, M. ; Serra, M. ; Lifrange, F....
ESMO Open. 8 (2023) 1 - p. 101239 , 2023

Link: https://doi.org/10.1016/..

5

176P Multiplex-immunoflourescence spatial patterns to predi..:

Garcia, A. Joaquin ; Krawczyk, J. ; Rediti, M....
Immuno-Oncology and Technology. 20 (2023) - p. 100635 , 2023

Link: https://doi.org/10.1016/..

6

34P Investigating morphological heterogeneity in luminal br..:

Occelli, N. ; Serra, M. ; Rediti, M....
ESMO Open. 8 (2023) 1 - p. 101258 , 2023

Link: https://doi.org/10.1016/..

7

179P Integrating multiplex immunofluorescence with gene exp..:

Rediti, M. ; Garcia, A. Joaquin ; Tissot, S....
Immuno-Oncology and Technology. 20 (2023) - p. 100638 , 2023

Link: https://doi.org/10.1016/..

8

59P Tumor cells-adipocytes interactions are associated with..:

Serra, M. ; Occelli, N. ; Rediti, M....
ESMO Open. 8 (2023) 1 - p. 101283 , 2023

Link: https://doi.org/10.1016/..

9

Clinical management of first-line advanced triple-negative ..:

Rediti, M ; Punie, K ; de Azambuja, E...
boreal:243846. , 2020

Link: http://hdl.handle.net/20..

10

Characterizing CDK12-Mutated Prostate Cancers:

Rescigno, P ; Gurel, B ; Pereira, R...
Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 27 (2), pp. 566 - 574. , 2020

Link: https://repository.icr.a..

11

Clinical management of first-line advanced triple-negative ..:

Rediti, M ; Punie, K ; de Azambuja, E...
boreal:243846. , 2020

Link: http://hdl.handle.net/20..

12

Early Post-treatment Prostate-specific Antigen at 4 Weeks a..:

Rescigno, P ; Dolling, D ; Conteduca, V...
European urology oncology, 2020, 3 (2), pp. 176 - 182. , 2020

Link: https://repository.icr.a..

13

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 p..:

Incorvaia L ; Fanale D ; Badalamenti G...
info:eu-repo/semantics/altIdentifier/wos/WOS:000588358600001. , 2020

Link: http://hdl.handle.net/10..

14

Immunological and clinicopathological features predict HER2..:

Rediti, Mattia ; Fernandez-Martinez, Aranzazu ; Venet, David...
Nature Communications. 14 (2023) 1 - p. , 2023

Link: https://doi.org/10.1038/..

15

Immunological and clinicopathological features predict HER2..:

Rediti, Mattia ; Fernandez-Martinez, Aranzazu ; Venet, David...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624889/. , 2023

Link: http://www.ncbi.nlm.nih...